Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 11/20 | 1.00 |
| ▸ | HTR2C | P28335 | 11/20 | 1.00 |
| ▸ | HTR1D | P28221 | 9/20 | 1.00 |
| ▸ | HTR2B | P41595 | 7/20 | 1.00 |
| ▸ | HTR1A | P08908 | 7/20 | 1.00 |
| ▸ | HTR6 | P50406 | 4/20 | 0.67 |
| ▸ | HTR4 | Q13639 | 3/20 | 0.67 |
| ▸ | HTR1B | P28222 | 3/20 | 0.67 |
| ▸ | HTR7 | P34969 | 3/20 | 0.67 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.67 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.67 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.38 |
| ▸ | HTR3B | O95264 | 1/20 | 0.38 |
| ▸ | HTR1E | P28566 | 1/20 | 0.38 |
| ▸ | HTR1F | P30939 | 1/20 | 0.38 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
| ▸ | HTR5A | P47898 | 1/20 | 0.38 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7000777 | 0.84 | HTR2A (0.73) | HTR2AHTR2CHTR1DHTR2BHTR1A | |
| SCHEMBL8177855 | 0.83 | HTR2C (1.00) | HTR2AHTR2CHTR1DHTR2BHTR1A | |
| SCHEMBL31105674 | 0.81 | HTR2A (0.68) | HTR2AHTR2CHTR1DHTR2BHTR1A | |
| SCHEMBL6092065 | 0.81 | HTR2C (1.00) | HTR2AHTR2CHTR1DHTR2BHTR1A | |
| SCHEMBL30390274 | 0.81 | HTR2C (1.00) | HTR2AHTR2CHTR1DHTR2BHTR1A | |
| SCHEMBL5936562 | 0.81 | HTR2C (1.00) | HTR2AHTR2CHTR1DHTR2BHTR1A | |
| SCHEMBL6094978 | 0.81 | HTR2C (1.00) | HTR2AHTR2CHTR1DHTR2BHTR1A | |
| SCHEMBL31105653 | 0.80 | HTR2A (0.80) | HTR2AHTR2CHTR1DHTR2BHTR1A | |
| Hydrochloric Acid SCHEMBL6092175 | 0.80 | HTR2C (0.98) | HTR2AHTR2CHTR1DHTR2BHTR1A | |
| Hydrochloric Acid SCHEMBL6093427 | 0.80 | HTR2C (0.98) | HTR2AHTR2CHTR1DHTR2BHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240252535-A1 | CELLULAR COMPOSITION FOR TREATMENT OF DISEASES, DISORDERS OR CONDITIONS AND METHOD OF USE | YZTHERAPEUTIC PERFORMANCE LTD. (IL) | 2024-08-01 | — | — | US | disclosed |
| EP-4208177-A1 | CELLULAR COMPOSITION FOR TREATMENT OF DISEASES, DISORDERS OR CONDITIONS AND METHOD OF USE | Yztherapeutic Performance Ltd. (IL) | 2023-07-12 | — | — | EP | disclosed |
| WO-2008083204-A2 | MODULATION OF NEUROGENESIS BY MELATONINERGIC LIGANDS | BRAINCELLS, INC. (US) | 2008-07-10 | — | — | WO | disclosed |
| US-20080167363-A1 | Modulation of Neurogenesis By Melatoninergic Agents | BRAINCELLS, INC (US) | 2008-07-10 | — | — | US | disclosed |
| US-20080167363-A1 | Modulation of Neurogenesis By Melatoninergic Agents | BRAINCELLS, INC (US) | 2008-07-10 | — | — | US | disclosed |
| EP-0885210-B2 | Tricylic compounds having binding affinity for melatonin receptors, their production and use | TAKEDA PHARMACEUTICAL (JP) | 2008-06-18 | — | — | EP | disclosed |
| EP-1550655-A1 | Bicyclic intermediates | Takeda Pharmaceutical Company Limited (JP) | 2005-07-06 | — | — | EP | disclosed |
| EP-0885210-B1 | Tricylic compounds having binding affinity for melatonin receptors, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2002-06-12 | — | — | EP | disclosed |
| EP-1199304-A1 | Bicyclic compounds and pharmaceutical composition containing tricyclic compound for treating or preventing sleep disorders | Takeda Chemical Industries, Ltd. (JP) | 2002-04-24 | — | — | EP | disclosed |
| EP-0708099-B1 | Tricyclic amide compounds, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2001-11-28 | — | — | EP | disclosed |
| US-6218429-B1 | TREATING MELATONIN RELATED DISORDERS (E.G. CIRCARDIAN RHYTHMS, SLEEP-AWAKE CYCLES, TIME ZONE CHANGES, SLEEP DISORDERS) | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-04-17 | — | — | US | disclosed |
| US-6071946-A | FOR TREATING DISORDERS OF THE MELATONINERGIC SYSTEM, SLEEP DISORDERS, CIRCADIAN RHYTHM DISORDERS | ADIR ET COMPAGNIE (FR) | 2000-06-06 | — | — | US | disclosed |
| US-6034239-A | BINDIG TO MELATONIN RECEPTORS; SLEEP DISORDERS; GLANDULAR DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-03-07 | — | — | US | disclosed |
| US-5998461-A | SLEEP DISORDERS | ADIR ET COMPAGNIE (FR) | 1999-12-07 | — | — | US | disclosed |
| EP-0885210-A1 | Tricylic compounds having binding affinity for melatonin receptors, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1998-12-23 | — | — | EP | disclosed |
| WO-1997032871-A1 | TRICYCLIC COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-09-12 | — | — | WO | disclosed |
| EP-0708099-A1 | Tricyclic amide compounds, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1996-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167363-A1 | Modulation of Neurogenesis By Melatoninergic Agents | MTNR1A, GAP43, DCX | HTR2A 120/4885HTR2C 277/4885HTR1D 853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.